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Abstract Long-acting (LA) preparations of methylphe-
nidate allow for once-daily dosing; however, pharmacoki-
netics may vary and depend on food intake. The objective
was to evaluate effectiveness of a two-phase release for-
mulation (Ritalin LA) under daily practice conditions.
This was a prospective, multicenter, observational study in
Germany. Eligibility and dosing were determined by the
physician based on the drug label. Outcomes included
changes over 3 months of treatment in assessments of
effect duration, clinical global impression (CGI), and
quality of life (ILK). In 101 sites, 262 patients (197 boys,
63 girls, and two unknown) with a mean age of 10.9 years
were enrolled; 50 were treated for the first time; 212
switched medication to Ritalin LA. After 3 months, CGI
improved in 59.4 % of patients, and well-being overall was
rated as good by 61.0 % of parents and 63.7 % of children.
Based on parents’ assessment, the proportion of children
suffering from strong disease burden decreased from 40.7
to 15.1 %. In 123 insufficient responders to previous
ADHD medications, benefit from Ritalin LA was above
average and effect duration was significantly prolonged as
compared to pretreatment. Overall, 28 patients (10.7 %)
had treatment-related adverse events with one case being
serious; 23 patients (8.8 %) discontinued therapy, 7
(2.7 %) due to poor treatment response; and 212 patients
(81 %) continued treatment beyond the study. In line with
clinical trial data, Ritalin LA provides significant benefit
also under routine practice conditions.
Keywords Methylphenidate  QoL  Treatment practice 
Observational study
Introduction
Attention-deficit hyperactivity disorder (ADHD) is among
the most common psychiatric disorders in children and
adolescents with an estimated prevalence of 3–5 %
(Dopheide and Pliszka 2009; Greenhill 1998; NIH 1998;
Scahill and Schwab-Stone 2000). This neurobiological
disorder is characterized by significant impairment of
concentration and attention, associated with a lack of
impulsivity control and increased motor activity (AWMF
2007). Without treatment, these symptoms may persist in
adulthood and adversely affect socioemotional and intel-
lectual development (Buitelaar and Medori 2010). Treat-
ment in children is usually multimodal comprising
psychotherapy together with occupational therapy, educa-
tional training including parents, and eventually drug
therapy (Brown et al. 2005; Dopheide and Pliszka 2009;
Grosse and Skrodzki 2007; Reddy 2013).
With more than 6,000 patients treated in over 200
clinical trials, methylphenidate (MPH) is one of the best
studied drugs in children and adolescents (Vitiello 2001).
Based on evidence of its efficacy from several clinical trials
and meta-analyses (Faraone et al. 2004; Group 1999;
Kutcher et al. 2004; Schachter et al. 2001), MPH has
become a mainstay in ADHD therapy and the first-line
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drug recommendation (AWMF 2007; Grosse and Skrodzki
2007; Reddy 2013). Conventionally, MPH treatment is
initiated with immediate release formulations to titrate the
dose (Kimko et al. 1999; Kutcher et al. 2004), usually
given two to three times daily, depending on the individual
effect duration and the severity of symptoms. After the
appropriate dose is determined, patients are often switched
to a long-acting (LA) formulation taken at home to avoid
drug intake in school or in the presence of peers ensuring
compliance and steadiness of effects (Grosse and Skrodzki
2007). For these reasons, more recent practice guidelines
recommend the use of modified-release formulations even
from the outset (National Collaborating Centre for Mental
Health 2009). Several modified-release formulations with
varying pharmacokinetic (PK) profiles are available, none
of which is preferentially recommended by treatment
guidelines. Advice given early on to choose the preparation
and then to titrate the dose according to individual
requirements (AWMF 2007; Banaschewski et al. 2008a,
2008b; Grosse and Skrodzki 2007) is still valid (Coghill
et al. 2013).
Due to the Spheroidal Oral Drug Absorption System
(SODAS) technology, Ritalin LA releases 50 % of the
drug immediately and 50 % after 4 h. This ensures effect
duration of 8–9 h with one single dose, regardless of food
intake (Markowitz et al. 2003). Independence from food
intake might be important, as children with ADHD have
different dietary patterns (Dura Trave et al. 2014), and only
about half of them were reported to have breakfast on a
regular basis (Oehler 2007). The efficacy and safety of this
modified-release formulation has been shown in placebo-
controlled (Biederman et al. 2003) and active-controlled
clinical trials (Lopez et al. 2003; Schulz et al. 2010; Silva
et al. 2005). However, despite high internal validity, clin-
ical trials are known to be prone to selection bias and to not
accurately reflect real-life conditions, particularly with
regard to compliance, which may considerably improve
with easier dosing regimens. Effectiveness in real life can
only be investigated by observational studies. Therefore,
the present study investigated the effectiveness of Ritalin
LA in an average pediatric ADHD population in Germany
over 3 months. The aim was to assess clinical benefits and




This was a multicenter, 12-week, observational study. For
each patient, physicians were requested to collect data
immediately prior to and about 1 month (optional) and
3 months after treatment initiation. Upon ethics committee
approval, the study was conducted from December 2008 to
August 2010 in compliance with the Declaration of Hel-
sinki and all applicable legal requirements in Germany.
Parents were informed about the study and had to consent
to participation of their child and to the analysis of its
pseudo-anonymized data. The study was registered on the
Web site of the German Association of Researching





As this was an observational study, there were no protocol
restrictions regarding eligibility of patients and their
treatment. Both were to be decided on by the attending
physician based on the drug label. This specifies (1) the
drug to be indicated for the treatment of ADHD with
hyperactive-impulsive or inattentive symptoms persistent
for at least 6 months and having caused clinically signifi-
cant impairment in at least two settings and (2) the dosage
to be adjusted according to the individual needs and
responses of patients. It recommends to start with 20 mg
once daily and to adjust in weekly 10 mg increments to a
maximum of 60 mg/day taken once in the morning. For
patients switching from another MPH formulation, it is
recommended to maintain the former total daily dose.
Outcome measures
Effectiveness was evaluated after 3 months of treatment
based on: (a) clinical global impression severity (CGI-s) of
patients as rated overall and regarding four aspects
(attention, impulse control, hyperactivity, and learning
problems) on a 4-point scale (inconspicuous, mildly/mod-
erately/severely abnormal) by the attending physician
(Dopfner et al. 2006). As this was an observational study in
over 100 centers, which rendered dedicated investigator
trainings unfeasible, changes in CGI were not rated sepa-
rately by the attending physician as suggested by Dopfner
and colleagues, but calculated as differences of CGI-s
scores; (b) patients’ quality of life (QoL) and disease
burden based on nine questions of the German inventory
for the assessment of QoL in children (ILK). These referred
to (1) coping with school demands, (2) relationship to
family members, (3) other children, (4) ease with self-
employment, (5), physical health, (6) general mood, (7)
overall well-being, (8) perceived disease, and (9) therapy
burden and were to be evaluated on a 5-point scale (very
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good, good, intermediate, rather poor, and very poor) by
parents and children (Mattejat and Remschmidt 2006).
Further outcome measures were the onset and the end of
any subjectively perceived effect as recorded by parents. In
addition, parents were asked at each visit whether breakfast
of their children over the preceding month had (in their
eyes) always been adequate, and whether quantity and
quality had varied.
Drug tolerability and safety were evaluated based on
adverse event (AE) monitoring at each scheduled visit and
treatment practice and compliance based on recordings of
dose, dose adjustments, concomitant medication, and pre-
mature discontinuation of the study medication.
Data management and analyses
All data were collected on paper Case Report Forms and
managed as well as analyzed by a Contract Research
Organisation (SIMW, Wegberg, Germany). Diseases were
classified according to the International Classification of
Diseases (ICD-10); medications according to the WHO
Drug Dictionary as of March 1, 2007; and AEs according
to the Medical Dictionary for Regulatory Activities
(MedDRA), version 13. Data analysis was mostly
descriptive using summary statistics for categorical and
quantitative data. Safety analyses included tabulation of
type and frequency of AEs, on a patient and event basis.
Inferential statistics were only applied for subgroup anal-
yses evaluating outcomes in patients having ceased previ-
ous treatment due to poor response (‘‘insufficient
responders’’) to examine potential benefits added by Rita-
lin LA. For this, Fisher’s exact test, Wilcoxon matched
pair test, and Mann–Whitney test were used at a signifi-
cance level of 0.05. All statistical analyses were performed




In total, 262 patients were enrolled in 101 sites across
Germany, 197 boys (75.2 %) and 63 girls (24.0 %); for two
children, sex had not been documented (0.8 %). Mean age
and weight were 10.9 ± 2.5 (SD) years and 41 ± 20 kg,
respectively. Disturbance of activity and attention (F90.0)
was most commonly diagnosed (58 %), followed by
hyperkinetic conduct disorder (F90.1: 34 %) and attention-
deficit disorder without hyperactivity (F98.8: 8 %). Fifty
patients (19.1 %) had new-onset ADHD and received drug
treatment for the first time. The remaining 212 patients
(80.9 %) switched to Ritalin LA, most frequently from
Medikinet retard (n = 64); less common premedications
were Concerta (35), Ritalin (33), Strattera (19), Equ-
asym (17), or Equasym retard (16). The most common
reason for changing drug treatment was poor response in
123 patients (58.0 %), followed by a preference for the
retarded formulation in 64 patients (30.2 %), and tolera-
bility problems in 37 (17.4 %). At baseline, the subgroup
of patients switching to Ritalin LA for poor effectiveness
(‘‘insufficient responders’’) was comparable to the
remaining population in demographic and disease charac-
teristics, with the exception of a higher percentage of male
patients (Table 1).
In comparison with the overall population, the subgroup
of patients newly treated with Ritalin LA (n = 50) had a
higher percentage of female patients (34 %), were more
often diagnosed with an attention-deficit disorder without
hyperactivity (16 %), and had less regularly adequate
breakfast (62 vs 46.2 % in the total population).
Table 1 Demographics, disease characteristics, and breakfast habits
in subgroups of patients with insufficient response to previous treat-








Age [years] 10.9 ± 2.4 10.8 ± 2.6 10.9 ± 2.5
Weight [kg] 40.4 ± 14.7 42.3 ± 23.1 41.4 ± 19.7
Sex
Male (%) 82.9 68.3 75.2
Female (%) 17.1 30.2 24.0
ICD-10 Diagnosis
F 90.0 (%) 58.5 57.5 58.0
F 90.1 (%) 36.6 31.7 34.0
F 98.8 (%) 4.9 10.1 7.6
Breakfast adequacy*


















* As judged by parents
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Effectiveness
Assessment of CGI-s by the physician
At the end of the study, the CGI-s in the total population
had improved in 137 (59.4 %) patients (Fig. 1). More
patients showed improvement in the area of inattentiveness
as compared with impulsivity control and hyperactivity
(64.4 vs 51.3 % and 44.8 % of patients, respectively).
Learning problems were reduced in 50.4 % of patients and
problems due to ADHD in general in 61.1 % of patients.
Assessment of QoL and disease burden by parents
and children
Mean scores on all nine items of the ILK had slightly
improved after 3 months of treatment (Fig. 2). At baseline,
parents rated the overall well-being in 101 (38.7 %) and the
mental condition in 74 (28.3 %) of the 262 children as
good. After 3 months of treatment, both rates increased to
61.0 %. Regarding the good overall well-being, the self-
assessment of children matched well (63.7 %), although
54.4 % already felt well at baseline; 39.0 % also rated their
mental condition at baseline to be good while in compar-
ison with parents less children did so after treatment
(47.7 %). By contrast, the rate of good physical health
hardly changed through treatment, neither for parents (77.7
vs 76.3 % at baseline) nor for children (64.1 vs 61.5 % at
baseline). Parents rated 40.7 % of children to cope well
with the demands at school as compared to 23.5 % at
baseline. Corresponding self-assessment of children was
slightly higher after treatment (47.0 %) and considerably
higher at baseline (36.3 %). According to parents, the
percentage of children with a good relationship to family
members and to fellows increased from 51.4 to 59.7 % and
from 45.1 to 57.7 %, respectively. Corresponding self-
assessments of children after 3 months matched well (56.9
and 54.9 % vs 52.7 % at baseline), although changes were
smaller. Good ability for self-entertainment had developed
in 54.6 % as compared to 44.6 % at baseline, as assessed
by parents. Self-assessments of children showed similar
changes at a lower level (46.9 vs 36.2 % at baseline).
Parents’ assessment of the disease burden to be strong
decreased from 40.7 to 15.1 % of their children and from
44.3 to 19.9 % for themselves. By contrast, only one-third
of children perceived the disease burden as strong without
any impact of treatment. The burden associated with
treatment was generally perceived low already at baseline
and hardly changed along with Ritalin LA, neither for
parents nor for children.
inattentiveness         impulsivity           hyperactivity
8.6 5.7






































Fig. 1 Change in the three aspects of the CGI-s (inattentiveness,
impulsivity, and hyperactivity) after 3 months of treatment with
Ritalin LA, as assessed by the investigator, in groups of patients who
switched treatment either for ‘‘non-response’’ to previous treatment
(n = 123) or for ‘‘other’’ reasons (n = 139)
0 1 2 3 4 5
Q1: coping with
school demands




 Q4: ease with
self-employment








Parents, 3 months baseline Children, 3 months baseline
Fig. 2 Mean scores (0: very poor to 5: very good) of parents and
children on the nine questions of the ILK at baseline and after
3 months of treatment
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Therapy was continued beyond the end of the study in
212 patients, whereas 23 patients (8.8 %) discontinued
treatment prematurely, 7 (2.7 %) because of poor treatment
response.
Effectiveness in subgroups of patients switching
from another ADHD medication to Ritalin LA
Among the patients switching ADHD medication, 59.3 %
of the 123 ‘‘insufficient responders’’ perceived a distinct
improvement with Ritalin LA as compared to 48.5 % of
89 patients switching for other reasons. The percentage of
patients with any improvement was about the same in both
groups (74.4 vs 74.6 %, respectively). The proportions of
insufficient responders showing improvements in inatten-
tiveness, impulsivity, and hyperactivity were comparable
to the remaining population (Fig. 1), and perceived
improvements regarding QoL and disease burden were also
about the same (Table 2).
The proportion of ‘‘insufficient responders’’ was par-
ticularly high (73.4 %) in the largest subgroup of patients
pretreated with Medikinet retard. Under Ritalin LA, the
CGI-s of these patients improved more often than average
(64.3 vs 59.4 % in the total patient population; inatten-
tiveness: 67.3 vs 64.4 %; impulsivity: 60.7 vs 51.3 %; and
hyperactivity 44.6 vs 44.8 %, respectively). A similar trend
was observed with QoL scores of parents and children.
Ratings from parents showed an improvement after
12 weeks on all questions, most notably global impression
and psychological state/mood (47 and 48 % with
improvement, respectively). Self-assessment of children
also revealed an improvement after 12 weeks on all ques-
tions, including the global impression (43 %) and psy-
chological state/mood (60 %).
Ritalin LA showed a significantly prolonged duration
of effect perceived by parents as compared to the preceding
MPH medications (Table 3). This prolongation was more
pronounced in insufficient responders as compared to those
changing for other reasons (on average, 1.4 versus 0.5 h,
Table 3). There was also less variation in effect duration
with Ritalin LA.
Safety
A total of 63 AEs were reported in 36 (13.7 %) patients. In
three patients, AEs were considered serious due to hospi-
talization, one because of sleepiness, decreased appetite,
and activity, one for insufficient treatment response, and
one for unknown reasons. The latter two were thought to be
unrelated to treatment. Physicians deemed 46 of the non-
serious AEs at least possibly related to MPH. These
potentially related AEs occurred in 28 patients (10.7 %) of
whom 12 patients had one, 10 patients two, five patients
three, and one patient four such AEs. Overall, incidence
rates of potentially MPH-related and serious adverse events
were 10.3 and 0.4 % of patients, respectively. The most
frequent AEs were loss of appetite, abdominal pain, and
nausea, the most frequently affected System Organ Classes
(SOCs) were metabolism and nutritional as well as psy-
chiatric and nervous system disorders (Table 4). Severity
was mild in 30.2 %, moderate in 39.7 %, and severe in
22.2 % of AEs; 7.9 % of data were missing. By the end of
the study, more than half of the AEs had resolved
completely.
Discussion
This observational study aimed at evaluating benefits
offered by Ritalin LA to children with ADHD under
routine practice conditions in Germany. It demonstrated
improvements in ADHD symptoms and QoL, confirmed
overall good tolerability and safety, and revealed a longer
perceived effect duration versus previous treatments.
Comparable results regarding safety and effectiveness of
other sustained release MPH formulations in daily practice
have already been reported, particularly after switching
from immediate release formulations (Dopfner et al. 2011a,
2011b; Rothenberger et al. 2011). However, to our
knowledge, a significant prolongation of the perceived
effect under such conditions is described here for the first
time, although recently a change in the daily course of
Table 2 Change in QoL (Mattejat and Remschmidt 2006) for the
subgroups of insufficient responders to previous treatment and the






Parents -5.0 ± 5.6 (69) -4.2 ± 6.1 (80) 0.1875
Children -4.1 ± 5.3 (36) -3.4 ± 6.5 (51) 0.6040
Values are mean ± standard deviation (number of patients with data)
* Mann–Whitney test
Table 3 Effect duration [h] of the preceding MPH medication and
Ritalin LA, as assessed by parents at the baseline and the final visit,
respectively
Preceding MPH Ritalin LA P*
All changing patients 6.2 ± 2.0 (147) 7.3 ± 1.4 (224) \0.001
Subgroups changing for
Poor effectiveness 6.1 ± 2.0 (87) 7.5 ± 1.4 (103) \0.001
Other reasons 6.5 ± 2.0 (60) 7.0 ± 1.4 (119) 0.037
P** 0.139 0.023
Values are mean ± standard deviation (number of patients with data)
* Wilcoxon; ** Mann–Whitney test
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ADHD symptoms after switching to another LA formula-
tion has been reported under routine practice conditions too
(Froelich et al. 2014). Moreover, the study confirmed
preliminary data indicating children with ADHD to often
have irregular breakfast (Dura Trave et al. 2014; Oehler
2007) and overall the assessments of children and parents
regarding the impact of changes in ADHD symptoms on
QoL to match well.
Differences in effectiveness and in particular of effect
durations may be linked to different PK profiles exhibited
also by sustained release formulations (Auiler et al. 2002;
Banaschewski et al. 2008a; Coghill et al. 2013; Gonzalez
et al. 2002; Haessler et al. 2008; Liu et al. 2005; Lopez
et al. 2003; Markowitz et al. 2003). Medikinet retard and
Ritalin LA were shown not to be bioequivalent in fed
state, and this difference in PK profiles was assumed to be
of clinical relevance (Fleischhaker et al. 2010; Haessler
et al. 2008). PKs and effect duration of some sustained
release formulations including Medikinet retard are
known to vary with food intake (Midha et al. 2001),
whereas release patterns of others including Ritalin LA
are unaffected (Lee et al. 2003). In fact, the current study
confirmed children with ADHD to have irregular breakfast
habits (Oehler 2007). However, due to limitations mostly
inherent to the observational design, it can not conclusively
be answered whether the observed longer perceived effect
duration of Ritalin LA was actually resulting from its
specific PK characteristics. No PK measurements could be
performed, and subgroups were too small and heterogenous
for a comparison with each individual LA premedication.
Short-acting MPH formulations may have contributed to
the shorter effect duration of premedication in the whole
‘‘insufficient responder’’ group. Finally, results on effect
duration and on breakfast adequacy were based on sub-
jective assessments only which are prone to recall bias.
However, both subjective assessments as well as recall bias
should have affected the current and the preceding medi-
cation in the same way and may thus explain the spread of
results rather than the difference between treatments. In
terms of safety, AEs are generally known to be underre-
ported in observational studies. However, despite those
limitations, overall, our data are still supporting effective-
ness and tolerability of Ritalin LA in daily practice.
Controlled clinical trials are warranted to identify sub-
groups of patients who might benefit most.
Conclusion
Ritalin LA improved CGI and QoL in children with
ADHD under routine practice conditions. Results were in
line with those from controlled clinical trials although
further studies will be needed to investigate differences in
perceived effect durations.
Table 4 Incidence of adverse events (AEs) and serious adverse
events (SAEs) in 28 patients that physicians deemed at least possibly
related to MPH (adverse drug reactions, ADR), by System Organ




Preferred term N % N % N %
Total of patients 262 100 262 100 262 100
Patients with ADR 27 10.3 1 0.4 28 10.7
Metabolism and
nutritional disorders
11 4.2 1 0.4 12 4.6
Anorexia 11 4.2 1 0.4 12 4.6
Nervous system disorders 10 3.8 0 0.0 10 3.8
Dizziness 1 0.4 0 0.0 1 0.4
Agitation 2 0.8 0 0.0 2 0.8
Confusional state 1 0.4 0 0.0 1 0.4
Headache 2 0.8 0 0.0 2 0.8
Insomnia 3 1.1 0 0.0 3 1.1
Paralysis 1 0.4 0 0.0 1 0.4
Psychiatric disorders 9 3.4 1 0.4 10 3.8
Aggression 3 1.1 0 0.0 3 1.1
Depression 1 0.4 0 0.0 1 0.4
Affective disorder 1 0.4 0 0.0 1 0.4
Dysphemia 1 0.4 0 0.0 1 0.4
Mood swings 1 0.4 0 0.0 1 0.4
Emotional disorders of
childhood
1 0.4 0 0.0 1 0.4
Sleep disorder 1 0.4 1 0.4 1 0.4
Gastrointestinal disorders 8 3.1 0 0.0 8 3.1
Nausea 4 1.5 0 0.0 4 1.5




2 0.8 1 0.4 3 1.1
Decreased activity 0 0.0 1 0.4 1 0.4
Rebound effect 1 0.4 0 0.0 1 0.4
Asthenia 1 0.4 0 0.0 1 0.4
Investigations 3 1.1 0 0.0 3 1.1
Weight decreased 3 1.1 0 0.0 3 1.1
Skin and subcutaneous
tissue disorders
1 0.4 0 0.0 1 0.4
Rash 1 0.4 0 0.0 1 0.4
Respiratory, thoracic and
mediastinal disorders
1 0.4 0 0.0 1 0.4
Chest discomfort 1 0.4 0 0.0 1 0.4
Social circumstances 1 0.4 0 0.0 1 0.4
Educational problem 1 0.4 0 0.0 1 0.4
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